282 related articles for article (PubMed ID: 31231778)
1. Targeting Translation of mRNA as a Therapeutic Strategy in Cancer.
Pal I; Safari M; Jovanovic M; Bates SE; Deng C
Curr Hematol Malig Rep; 2019 Aug; 14(4):219-227. PubMed ID: 31231778
[TBL] [Abstract][Full Text] [Related]
2. The biological and therapeutic relevance of mRNA translation in cancer.
Blagden SP; Willis AE
Nat Rev Clin Oncol; 2011 May; 8(5):280-91. PubMed ID: 21364523
[TBL] [Abstract][Full Text] [Related]
3. Targeting the translation machinery in cancer.
Bhat M; Robichaud N; Hulea L; Sonenberg N; Pelletier J; Topisirovic I
Nat Rev Drug Discov; 2015 Apr; 14(4):261-78. PubMed ID: 25743081
[TBL] [Abstract][Full Text] [Related]
4. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
5. Targeting translation regulators improves cancer therapy.
Jiang SL; Mo JL; Peng J; Lei L; Yin JY; Zhou HH; Liu ZQ; Hong WX
Genomics; 2021 Jan; 113(1 Pt 2):1247-1256. PubMed ID: 33189778
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.
Pettersson F; Del Rincon SV; Miller WH
Expert Opin Ther Targets; 2014 Sep; 18(9):1035-48. PubMed ID: 25004955
[TBL] [Abstract][Full Text] [Related]
7. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.
Alain T; Morita M; Fonseca BD; Yanagiya A; Siddiqui N; Bhat M; Zammit D; Marcus V; Metrakos P; Voyer LA; Gandin V; Liu Y; Topisirovic I; Sonenberg N
Cancer Res; 2012 Dec; 72(24):6468-76. PubMed ID: 23100465
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G.
Moerke NJ; Aktas H; Chen H; Cantel S; Reibarkh MY; Fahmy A; Gross JD; Degterev A; Yuan J; Chorev M; Halperin JA; Wagner G
Cell; 2007 Jan; 128(2):257-67. PubMed ID: 17254965
[TBL] [Abstract][Full Text] [Related]
9. Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate).
Novotny L; Al-Tannak NF; Hunakova L
Neoplasma; 2016; 63(4):495-503. PubMed ID: 27268912
[TBL] [Abstract][Full Text] [Related]
10. Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.
Musa J; Orth MF; Dallmayer M; Baldauf M; Pardo C; Rotblat B; Kirchner T; Leprivier G; Grünewald TG
Oncogene; 2016 Sep; 35(36):4675-88. PubMed ID: 26829052
[TBL] [Abstract][Full Text] [Related]
11. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
12. The 4E-BP1/eIF4E ratio is a determinant for rapamycin response in esophageal cancer cells.
Hsu HS; Lin MH; Jang YH; Kuo TT; Liu CC; Cheng TH
J Thorac Cardiovasc Surg; 2015 Jan; 149(1):378-85. PubMed ID: 25439783
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.
Malka-Mahieu H; Newman M; Désaubry L; Robert C; Vagner S
Clin Cancer Res; 2017 Jan; 23(1):21-25. PubMed ID: 27789529
[TBL] [Abstract][Full Text] [Related]
14. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
16. Phenethyl isothiocyanate, a cancer chemopreventive constituent of cruciferous vegetables, inhibits cap-dependent translation by regulating the level and phosphorylation of 4E-BP1.
Hu J; Straub J; Xiao D; Singh SV; Yang HS; Sonenberg N; Vatsyayan J
Cancer Res; 2007 Apr; 67(8):3569-73. PubMed ID: 17440067
[TBL] [Abstract][Full Text] [Related]
17. Translating Hedgehog in Cancer: Controlling Protein Synthesis.
D'Amico D; Canettieri G
Trends Mol Med; 2016 Oct; 22(10):851-862. PubMed ID: 27591077
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents.
Fan A; Sharp PP
J Med Chem; 2021 Mar; 64(5):2436-2465. PubMed ID: 33592144
[TBL] [Abstract][Full Text] [Related]
19. Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.
Jin J; Xiang W; Wu S; Wang M; Xiao M; Deng A
Biochem Biophys Res Commun; 2019 Mar; 510(4):580-586. PubMed ID: 30739792
[TBL] [Abstract][Full Text] [Related]
20. Defect in the regulation of 4E-BP1 and 2, two repressors of translation initiation, in the retinoid acid resistant cell lines, NB4-R1 and NB4-R2.
Grolleau A; Wietzerbin J; Beretta L
Leukemia; 2000 Nov; 14(11):1909-14. PubMed ID: 11069026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
